Oxidative Stress {#S1}
================

Most eukaryotic organisms need oxygen to ensure the normal functioning of cellular energy metabolism, which is an evolutionary advantage and a highly efficient form of energy production ([@B226]). In the electron transport chain (ETC), oxygen is partially reduced by the incorporation of an electron, generating a free radical as a secondary product ([@B141]; [@B490]). Free radicals are atoms or molecules that have one or more unpaired electrons in their last orbital layer ([@B74]), which makes them strongly reactive capable of carrying out chain reactions, responsible for the oxidative damage of cells and tissues ([@B444]). They are classified as ROS and reactive nitrogen species (RNS) ([@B112]). Also included are reactive iron species (RIS) ([@B123]) and copper species (RCS) ([@B186]). The main ROS are: superoxide anion radicals (O$_{2}^{\bullet -}$), hydroxyl radicals (OH^∙^) and hydrogen peroxide (H~2~O~2~) ([@B373]). The RNS include: nitric oxide radical (NO^∙^), nitroxyl anion (NO^--^), nitrosonium cation (NO^+^) and peroxynitrite anions (ONOO^--^) ([@B190]; [@B401]; [@B535]).

The production of ROS is mainly secondary to enzymatic reactions involved in the respiratory chain, activity of cytochrome p-450, synthesis of prostaglandins and phagocytosis ([@B369]). Mitochondrial activity and metabolism of cytochrome p-450 are the most contributing sources in mammalian cells ([@B224]) ([Figure 1](#F1){ref-type="fig"}).

![Physiopathogenesis of ALS. Oxidative stress is caused by an imbalance between antioxidant defenses and RONS in favor of these second ones. The endogenous production of ROS is secondary to different prooxidant agents: mitochondrial and cytochrome p-450 metabolism, prostaglandins synthesis, phagocytosis, NADPH oxidases, XO, LOX and COX. Among the endogenous sources of RNS it should be noted the activity of epithelial, neuronal and inducible NOS. Exogenous sources also can produce RONS: stress, tobacco, UV-light, pesticides, environmental pollution and malnutrition. OS affects the normal functioning of the ETC, producing mitochondrial dysfunction that generates more ROS, which leads to a "vicious-cycle" that increases metabolic stress. This situation characterizes neurodegenerative diseases such as: ALS, AD, PD, MS, HD, and SA. In the case of ALS, OS and mitochondrial dysfunction have been identified as two mechanisms involved in its pathogenesis. They are related to neuroinflammation, aggregation of TDP-43, mutations in the mtDNA that produce characteristic OS biomarkers such as 8-OHdG, aggregation of SOD1 which impairs energy metabolism and cellular respiration, affectation of ATP supply to neurons and disturbance of the intracellular calcium homeostasis that results in excitotoxicity. The formation of highly reactive end products such as MDA and 4-HNE, both secondary to the lipoperoxidation of the neuronal membranes, is also observed.](fphys-11-00063-g001){#F1}

Mitochondrial production of ROS may occur on the external membrane, internal membrane or in the mitochondrial matrix, during physiological and pathological conditions ([@B369]). O$_{2}^{\bullet -}$ production occurs when there is a buildup of nicotinamide adenine dinucleotide phosphate (NADPH) or when there is a reduced CoQ pool within the mitochondria ([@B328]). O$_{2}^{\bullet -}$ may also be secondary to the enzymatic activity of lipoxygenases (LOX) and cyclooxygenases (COX) ([@B476]) during the arachidonic acid metabolism and by endothelial and inflammatory cells ([@B14]). O$_{2}^{\bullet -}$ may participate in reactions that produce H~2~O~2~ or OH^∙^ ([@B258]) ([Figure 1](#F1){ref-type="fig"}).

The cytochrome p-450 enzymes present in the liver are an important source of ROS production and their function is to catalyze O$_{2}^{\bullet -}$ producing reactions by NADPH dependent mechanisms ([@B280]). The risk of ROS production here is high because it contains transition ions, oxygen and electron transfer processes ([@B280]). In addition, there are a group of NOX (NADPH oxidases) enzymes located on the cell membrane of polymorphonuclear cells, macrophages and endothelial cells, that facilitate the conversion of oxygen into superoxide on biological membranes using NADPH as an electron donor with ROS released as secondary products ([@B25]) ([Figure 1](#F1){ref-type="fig"}). Endothelium xanthine dehydrogenase interacts with xanthine oxidase (XO) producing O$_{2}^{\bullet -}$ and H~2~O~2~, and thus, generating another source of free radicals ([@B473]) ([Figure 1](#F1){ref-type="fig"}).

Non-enzymatic reactions may also be responsible for the production of ROS by the reaction of oxygen with organic compounds and after cellular exposure to ionizing radiation ([@B476]) ([Figure 1](#F1){ref-type="fig"}).

The endogenous release of RNS, such as nitric oxide (NO^∙^), is produced from [L]{.smallcaps}-arginine in reactions of catalyze by three main isoforms of nitric oxide synthase (NOS): epithelial NOS, neuronal NOS and inducible NOS, which are activated in response to various endotoxin or cytokine signals ([@B152]). Thus oxygen can react with this NO^∙^ and form highly reactive molecules such as ONOO^--^ ([@B413]; [@B430]) ([Figure 1](#F1){ref-type="fig"}).

Endogenous production of reactive oxygen and nitrogen species (RONS) can be conditioned by exogenous pro-oxidant factors: environmental and atmospheric pollution, water pollution, chemicals like pesticides or industrial solvents, heavy metals or transition metals, different types of xenobiotics, irradiation by UV-light, X-rays or gamma rays, stress, tobacco, smoked meat, the use of waste oil and malnutrition ([@B366]; [@B334]; [@B444]; [@B524]) ([Figure 1](#F1){ref-type="fig"}).

Reactive oxygen and nitrogen species at physiological concentrations are regulators of numerous cellular functions: cellular signaling pathway, control of cell survival, regulation of vascular tone, signal transduction by cell membrane receptors, membrane renewal, synthesis and release of hormones, increase of inflammatory cytokine transcription regulation of the immune system ([@B399]; [@B388]), phosphorylation of proteins, action on ionic channels and transcription factors, production of thyroid hormones and crosslinking on extracellular matrix ([@B56]).

The body tries to maintain redox homeostasis between the production of RONS and the capacity for their removal by antioxidant systems ([@B535]), which allows the redox state to be re-established after temporary exposure to high concentrations of RONS and minimize the risk of a deteriorated redox homeostasis, which is an unbalanced state known as OS ([@B436]; [@B104]; [@B277]) ([Figure 1](#F1){ref-type="fig"}). However, redox homeostasis is conditioned by the magnitude and duration of exposure to free radicals, since constant exposure can have a serious impact on intracellular signals or genetic expression, resulting in irreversible pathological consequences ([@B394]), since most reactions of the body are dependent on the redox state ([@B457]).

Diseases associated with OS, such as neurodegenerative diseases, are related to aging ([@B277]), a physiological stage accompanied by progressive loss of tissue and organ function ([@B149]), changes in regulatory processes, decrease in the antioxidant capacity of the organism and irreversible tissue damage by RONS that compromises the achievement of a redox balance ([@B403]). The damage caused by oxidation depends on the defects of the enzymes involved in the redox signaling pathways ([@B457]).

Free radicals can cross the cells and cause modifications in the main macromolecules (lipids, proteins and nucleic acids), damaging their structure and altering their normal function ([@B413]). Lipid peroxidation is associated with different disease states and is responsible for an unstable cell membrane, oxidation of low-density lipoproteins (LDL) and poly-unsaturated fatty acids (PUFAs). The oxidation of different amino acids such as lysine, arginine, proline and threonine results in protein dysfunction. Oxidative damage of DNA generates severe mutations and adverse effects on transcription, producing an RNA more vulnerable to oxidation. Chronic persistence of this situation is capable of causing cell death ([@B206]; [@B124]).

OS plays an important role in chronic, inflammatory pathologies ([@B242]), progressive brain damage and the pathogenesis of neurodegenerative diseases such as: Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Multiple sclerosis (MS), Huntington's disease (HD), and Spinocerebellar ataxia (SA) ([@B119]; [@B214]; [@B524]) ([Figure 1](#F1){ref-type="fig"}).

Oxidative Stress and Neurodegenerative Diseases {#S2}
===============================================

The exact pathogenesis of neurodegenerative diseases remains unknown, although a complex and multifactorial origin has been established in which aspects such as genetic predisposition, certain endogenous factors and exposure to environmental factors are involved ([@B100]; [@B99]; [@B97]). ROS is a key factor in the etiology of these pathologies ([@B43]) and in patients with a neurodegenerative disease, high levels of OS biomarkers have been observed ([@B450]; [@B334]). However, physiological concentrations of free radicals play an important role in normal brain function ([@B113]; [@B426]; [@B78]). Thus, ROS can contribute to: vascularization, cerebral perfusion, cellular signaling, synaptic plasticity, neurotransmitter secretion and cerebral vasodilation ([@B301]; [@B175]; [@B331]). A moderate increase of ROS secondary to mitochondrial activity produces preconditioning that leads to a neuroprotective function against harmful agents and is even preventive against massive ROS formation ([@B122]; [@B233]; [@B121]). The origin of the problem lies in impaired redox homeostasis, which causes damage to cell membrane, compromising the viability and integrity of the central nervous system (CNS) ([@B484]; [@B359]). The excess of ROS is related to changes in the microcirculation of the brain ([@B154]; [@B449]). O$_{2}^{\bullet -}$ and H~2~O~2~ are able to cause a contraction of cerebral blood vessels ([@B15]). Increased levels of H~2~O~2~ are associated with increased pro-apoptotic agents in brain vascular cells ([@B270]) and OS can alter cerebral vascular function through an interruption of NO^∙^ signaling and consequently, its vasodilatory and anti-inflammatory capacity ([@B313]; [@B113]). In addition, ROS contribute to the maintenance of a proinflammatory state, secondary to secretion of cytokines and chemokines ([@B202]; [@B242]).

The CNS is especially susceptible to oxidative damage ([@B98]). The brain is largely formed by PUFAs with high sensitivity to lipid peroxidation ([@B343]), motor neurons are highly sensitive to OS ([@B437]) and the CNS has a poor antioxidant capacity with low activity of protective enzymes such as glutathione peroxidase (GPx), catalase (CAT) or superoxide dismutase (SOD) and poor capacity for cell regeneration ([@B147]; [@B247]; [@B151]). Although the brain only accounts for 2% of body weight ([@B309]) and mitochondrial density is higher in myocytes than in neuronal cells ([@B159]), it is an organ with a high metabolic rate that can consume up to 20% of the total oxygen of the body ([@B325]; [@B404]). This means it has 10 times higher energy and glucose consumption than the other tissues and a high dependence on mitochondrial energy production, responsible for the increase of ROS ([@B71]). Taking into account the high rate of demand and energy consumption of the brain, the majority of mitochondrial mutations can affect the functioning of the CNS and have been associated with neurodegenerative diseases ([@B20]). Thus, mitochondrial dysfunction is currently seen as a "convergence point" in neurodegeneration ([@B99]; [@B40]; [@B23]; [@B260]).

Mitochondrial dysfunction compromises the energy supply of ATP to neurons, calcium homeostasis and leads to high levels of ROS that accelerate the mutation rate of mitochondrial DNA (mtDNA) and lipoperoxidation of neuronal membranes, causing decomposition of PUFAs and the formation of highly reactive end products: malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE) (the most toxic species related to cell damage and apoptosis) ([@B364]; [@B10]; [@B155]) ([Figure 1](#F1){ref-type="fig"}). Accumulation of mutations in mtDNA causes an increase in oxidative damage, a decrease in energy rate and an increase in ROS. Thus, mitochondrial dysfunction generates a "vicious-cycle" responsible for neuronal damage, genetic mutations and metabolic stress, a situation that can lead to apoptosis ([@B485]; [@B427]; [@B500]).

Mitochondrial dysfunction is considered as the main cause of neurodegenerative diseases pathogenesis (ALS, PD, AD, MS, HD) ([@B278]; [@B142]) ([Figure 1](#F1){ref-type="fig"}). Postmortem studies in brains of patients with these diseases have found that mitochondrial dysfunction is a common event leading to the degeneration and death of neuronal cells ([@B424]; [@B31]; [@B128]).

Brain aging increases sensitivity to OS and decreases the effectiveness of antioxidant defenses, causing functional deficiencies, inflammation, decreased elasticity and greater susceptibility to the etiological factors involved in the pathogenesis of neurodegenerative disease ([@B142]; [@B182]). It also contributes to the accumulation of mutations in the mtDNA, malfunctions in the oxidative phosphorylation pathway and impaired redox homeostasis ([@B416]).

ROS have currently been proposed as one of the main contributors to the development and progression of neurodegenerative diseases ([@B324]). There is evidence that indicates that the increase in RONS concentration is a inducer of tissue damage, activation of microglia and astrocytes, neuronal dysfunction, neurodegeneration and cell death ([@B142]; [@B324]; [@B422]). Thus, a "vicious cycle" between OS, mitochondrial dysfunction, aging and neuroinflammation has been demonstrated ([@B506]; [@B482]). However, further studies are necessary to understand the physiopathological mechanisms implicated ([@B421]) because it is unknown whether OS is a primary cause that induces the initiation of neurodegenerative diseases or if it is a side effect associated with the spread of damage to nerve cells ([@B221]; [@B136]).

Amyotrophic Lateral Sclerosis {#S3}
=============================

ALS, also known as Charcot's disease or Lou Gehrig's disease, was originally described by Jean-Martin Charcot and Joffrey ([@B79]; [@B334]) and is the most common motor neuron disease ([@B389]). It causes a selective loss of upper motor neurons (UMN) of the motor cortex and lower motor neurons (LMN) of the brainstem and spinal cord ([@B59]; [@B475]).

Patients with ALS develop weakness, muscle denervation, atrophy and progressive paralysis of all muscles (bulbar and respiratory), dysphagia ([@B12]; [@B109]; [@B172]) and respiratory muscle weakness that leads to respiratory failure and death ([@B429]). The survival rate is 3--5 years after the onset of symptoms ([@B18]; [@B170]; [@B89]; [@B505]).

The incidence and prevalence of ALS vary according to the geography and design of the study ([@B298]; [@B241]) and there are differences between African--American and Hispanic populations ([@B171]). The incidence is 2--3 cases for every 1.000.000 inhabitants/year and prevalence of 4.6 -- 5 for every 100.000 inhabitants in Western European countries ([@B84]; [@B455]). A significant increase in the overall prevalence of ALS to 8.58 cases per 100.000 people is expected by the year 2020 and to 9.67 per 100,000 people by 2116. In the United Kingdom prevalence in the 2010 year was 1415 cases and is projected to increase to 1701 by 2020 and 2635 by 2116 ([@B172]).

ALS typically occurs in white adults between the ages of 50--60 ([@B84]; [@B305]), and cases in children are very rare ([@B300]; [@B33]; [@B211]). The age of onset is earlier in men than in women and men are more prone to spinal involvement, whereas bulbar involvement is more common in women ([@B304]).

ALS is classified into two types: familial ALS (fALS) and sporadic ALS (sALS). fALS represents approximately 5--10% of the cases and is related to heterogeneous mutations of a set of genes with an autosomal dominant inheritance pattern ([@B319]). Up to 20% of cases of fALS is due to a mutation of the gene that encodes the enzyme Cu-Zn superoxide dismutase (SOD1). sALS occurs in up to 90--95% of the cases but its origin is still unknown ([@B300]; [@B19]; [@B351]). fALS and sALS can affect any voluntary muscle but their presentation, phenotype and progression are variable ([@B502]), hindering differential diagnosis ([@B452]; [@B163]; [@B481]). ALS may manifest double onset: involvement of the extremities (80% of cases) or bulbar involvement (20% of cases) ([@B356]).

The death of motor neurons results in a characteristic clinical feature: spasticity, muscular weakness and atrophy, hyperreflexia, cramps, fasciculation, Babinski sign, loss of coordination, paralysis of voluntary musculature, dysphagia and difficulties in swallowing, speech and respiration ([@B503]; [@B534]; [@B444]). It is associated with metabolic disorders such as weight loss, hypermetabolism and hyperlipidemia ([@B131]). fALS and sALS do not affect the senses (sight, smell, taste, hearing and touch) ([@B145]).

Several factors have been identified related to the pathogenesis of ALS: OS, mitochondrial dysfunction, neuroinflammation, excitotoxicity due to an increase in the neurotransmitter glutamate, defect in axonal transmission and in the metabolism of RNA, apoptosis, cytoskeletal abnormalities, disruption of membrane trafficking, endoplasmic reticulum stress, protein misfolding and aggregation ([@B355]; [@B49]; [@B362]; [@B51]; [@B523]) and cysteine modifications like oxidation or palmitoylation that contribute to a general aberration of cysteine residues proteostasis ([@B477]). A relationship has been established between environmental conditions and the epidemiology of ALS: alcohol, tobacco, sedentary lifestyle, fungal and viral infections or exposure to electromagnetic radiation ([@B521]).

There are currently no effective treatments for ALS and therapy is limited to symptomatic and palliative treatment ([@B45]). Riluzole ([@B316]) and edaravone ([@B406]) are the only approved pharmacological therapies that increase the survival rate by 2--3 months ([@B127]; [@B196]), but edaravone is only beneficial to a subset of people with early stage ALS ([@B1]). Other therapeutic routes indicate multidisciplinary treatment involving: nurses, dieticians, nutritionists, occupational therapists, physical therapists, psychologists, social workers and speech therapists ([@B170]).

Oxidative Stress and Amyotrophic Lateral Sclerosis {#S4}
==================================================

Presence of OS biomarkers and high levels of ROS have been determined in the CNS regions specifically in ALS patients ([@B164]), which indicates that impaired redox homeostasis is a relevant factor and associated with the development and progression of neurodegeneration in fALS and sALS ([@B70]; [@B363]; [@B441]). High levels of certain types of ROS (H~2~O~2~ and O$_{2}^{\bullet -}$) have been observed in affected cells ([@B36]).

Loss of oxidative control and excessive ROS production are particularly linked to the mutated forms of SOD1 ([@B144]; [@B197]; [@B20]), which can have up to 150 different types of mutations ([@B158]; [@B13]). SOD1 is an antioxidant enzyme that catalyzes the conversion of O$_{2}^{\bullet -}$ into H~2~O~2~ and O~2~, and is key in the regulation of OS, cell damage ([@B303]; [@B273]; [@B360]), energy metabolism and cellular respiration ([@B412]). Oxidation and/or misfolding of SOD1 results in a deterioration in the regulation of the above processes, mitochondrial dysfunction and increase in the production of superoxides ([@B216]; [@B367], [@B368]; [@B395]). Its mutation predisposes cellular organelles to oxidative damage ([@B115]; [@B7]) and excessive levels of ROS that attack astrocytes ([@B214]). OS contributes to the aggregation of SOD1 ([@B60]) enhancing mitochondrial dysfunction ([@B281]; [@B492]).

The transgenic mouse model of ALS (SOD1^G93A^) has enabled the identification of pathogenic mechanisms and the establishment of a "vicious cycle" between: OS, mitochondrial dysfunction and deterioration of the ETC ([@B235]; [@B308]; [@B365]; [@B508]). Most of the oxidative species that are formed in the CNS are secondary to oxidative phosphorylation ([@B57]; [@B29]; [@B238]) and mitochondrial dysfunction is the largest source of ROS production, so is a clear sign of affectation of motor neurons in the spinal cord and the motor cortex ([@B39]; [@B240]; [@B286]; [@B105]). Mitochondrial damage causes an alteration in intracellular calcium levels and in normal functioning of the ETC ([@B51]) that contributes to the increase of ROS and to the activation of chain reactions that lead to greater oxidative damage, reinforcing the "vicious cycle" ([@B193]; [@B142]; [@B402]; [@B284]; [@B483]) and increasing cellular susceptibility to apoptosis ([@B179]; [@B217]).

Changes in antioxidant defense markers have been observed in patients with ALS ([@B102]). However, the results are random, due to the wide heterogeneity, form of presentation and variability of the pathogenic mechanisms of the disease ([@B230]). Low levels of reduced glutathione (GSH) in erythrocytes ([@B27]) and in the motor cortex ([@B208]) of patients with ALS, a systemic pro-inflammatory state (increased levels of IL-6 and IL-8) and an impaired antioxidant system ([@B134]) have been highlighted. One study compared *in vivo* levels of GSH in the motor cortex of 11 ALS patients with those in 11 age-matched healthy volunteers and determined that GSH levels were 31% lower in ALS patients than in healthy volunteers ([@B503]). Also, decreased glutathione levels caused motor neuron degeneration in the hSOD1^wt^ over-expressing mice model (hemizygous mice over-expressing wild-type hSOD1 at moderate levels) ([@B244]) and accelerated motor neuron death in SOD1^G93A^ mice ([@B360]). Catalase (CAT) activity is decreased in erythrocytes of sALS patients ([@B339]; [@B27]) and is significantly decreased compared to neurologically healthy controls ([@B164]).

Studies conducted *in vitro* indicated that oxidative damage to nerve cells (astrocytes and oligodendrocytes) was related to neurodegeneration ([@B372]). Oxidative imbalance decreases the number of glial cells and the ability to transmit the axonal signal ([@B357]).

Markers for OS have been determined in the cerebrospinal fluid (CSF), tissues, blood and urine of patients with ALS ([@B48]). After postmortem analysis of neuronal tissues in sALS and fALS patients, an increase of OS biomarkers was noted in proteins, lipids and DNA ([@B35]; [@B4]; [@B249]; [@B472]; [@B54]). The most frequently studied biomarkers include: carbonylated and/or glycosylated proteins, lipid peroxidation and DNA damage ([@B433]).

In the nervous tissues of ALS patients, high levels of carbonylated proteins have been measured in the motor cortex ([@B417]; [@B178]; [@B458]) and high levels of advanced products of protein oxidation in the plasma of the erythrocytes of sALS patients ([@B285]). In ALS-mouse models, non-functional proteins secondary to the oxidation of amino acid residues by peroxynitrite have been observed ([@B519]). In addition, oxidative damage results in the aggregation of TDP-43, the major disease-associated protein involved in the pathogenesis of ALS ([@B327]; [@B345]) that promotes OS in neuronal cells ([@B129]; [@B91], [@B90]; [@B291]) ([Figure 1](#F1){ref-type="fig"}).

CNS lipids are susceptible to oxidative damage ([@B337]) and lipoperoxidation generates high levels of HNE, MDA ([@B381]) and F2-isoprostane (F2-IsoPS) ([@B317]; [@B312]; [@B486]) ([Figure 1](#F1){ref-type="fig"}). In the CSF of patients with ALS, high levels of HNE and 3-nitrotyrosine (3-NT) have been obtained ([@B438]; [@B130]; [@B361]; [@B26]; [@B415]).

The guanine contained in DNA is highly susceptible to oxidation and acts as a target for ROS ([@B267]; [@B77]). 8-oxo-deoxyguanosine (8-OHdG) can be considered as a specific biomarker of oxidation of the motor cortex in ALS ([@B95], [@B96]; [@B207]; [@B320]) ([Figure 1](#F1){ref-type="fig"}). Increased levels of 8-OHdG and isoprostanoids have been observed in the urine of subjects affected by the disease compared to the control group ([@B314]).

The evaluation of GPx activity, glutathione reductase (GR), SOD, total serum antioxidant status (TAS), MDA and 8-OHdG in ALS patients, found a significant decrease in TAS levels and an increase of 8-OHdG and MDA levels, together with significantly higher oxidized/reduced glutathione (GSSG/GSH) ratio and IL-6 and IL-8 ([@B48]).

Antioxidants and Amyotrophic Lateral Sclerosis {#S5}
==============================================

The evidence implicates free radicals and OS as factors related to the pathogenesis of ALS. Interest has focused on substances with antioxidant potential such as: vitamin E, carotenes, flavonoids, resveratrol, epigallocatechin gallate, curcumin, Co-enzyme Q10, melatonin and edaravone as useful agents in the management of this disease ([Table 1](#T1){ref-type="table"}).

###### 

Antioxidant compounds used in the treatment of ALS.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antioxidant         Features                                                                                                 Molecular mechanisms                                                                    Curative effects and treatment object                                                                      References
  ------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------
  Vitamin E           \- Lipophilic antioxidant\                                                                               \- Protection against   lipoperoxidation\                                               \- Delay in the clinical onset of   the disease\                                                           [@B184]; [@B116]; [@B24]; [@B489]; [@B495]
                      - Ability to cross cell   membrane                                                                       - Protection against ROS   and RNS                                                      - Increase GSH levels in   plasma\                                                                         
                                                                                                                                                                                                                       - Lower risk of dying by ALS\                                                                              
                                                                                                                                                                                                                       - Significant decrease in the   risk of the disease\                                                       
                                                                                                                                                                                                                       - Lower ALS rates                                                                                          

  Carotenes           \- Natural pigments\                                                                                     Antioxidant and neutralizing properties against ROS                                     \- Help prevention and/or delay   the onset of ALS\                                                        [@B148]; [@B256]
                      - Different types:   ß-carotene, lutein,   astaxanthin and   lycopene                                                                                                                            - Reduced risk of ALS\                                                                                     
                                                                                                                                                                                                                       - Treating neuroinflammation   and apoptosis                                                               

  Flavonoids          \- Natural substances of   fruits and vegetables\                                                        \- Protection against ROS\                                                              \- Improve motor deficits and   enhance lower neuronal   survival\                                         [@B252]; [@B213]; [@B499]
                      - Different types: 7,8-DHF,   fisetin and quercetein                                                     - Modulate metabolic   pathways                                                         - Reduction of intracellular   ROS levels\                                                                 
                                                                                                                                                                                                                       - Reduction of motor neuron   loss\                                                                        
                                                                                                                                                                                                                       - Improve motor activity and   survival rate\                                                              
                                                                                                                                                                                                                       - Inhibition of aggregation and   misfolding of SOD1                                                       

  Resveratrol         \- Natural polyphenolic   compound\                                                                      \- Interacts with mutant   SOD1 (G93A) protein\                                         \- Delays the onset of ALS\                                                                                [@B292], [@B293]; [@B445]
                      - In grapes, peanuts and   berries\                                                                      - Up-regulates SIRT1\                                                                   - Increases survival of spinal   motor neurons\                                                            
                      - Produced in plants in   response to mechanical   injury, fungal infection,   and UV radiation\         - Down-regulation of   AMPK/SIRT1 signaling in   bone marrow mesenchymal   stem cells   - Preserves the function of the   lower and upper motor neuron\                                            
                      - Scavenger of free   radicals                                                                                                                                                                   - Attenuates the loss of motor   neurons\                                                                  
                                                                                                                                                                                                                       - Improves muscle atrophy\                                                                                 
                                                                                                                                                                                                                       - Improves mitochondrial   function of muscle fibers                                                       

  Epigallocatechin\   \- Catechin present in   green tea\                                                                      \- Modulates mitochondrial   responses to OS\                                           \- Prevents OS-induced death\                                                                              [@B250], [@B251]; [@B510]\
  gallate             - Crosses the blood-brain   barrier                                                                      - Protection against   lipoperoxidation\                                                - Delays the outbreak or   progression of ALS\                                                             
                                                                                                                               - Changes intracellular   signals\                                                      - Delays the onset of the   disease\                                                                       
                                                                                                                               - Reduces the   concentration of NF-kB   caspase-3 and iNOS                             - Prolongs useful life\                                                                                    
                                                                                                                                                                                                                       - Increases the number of   motor neurons\                                                                 
                                                                                                                                                                                                                       - Decreases the activation of   microglia                                                                  

  Curcumin            \- Natural and liposoluble   dye\                                                                        \- Activates Nrf2\                                                                      \- Improves survival\                                                                                      [@B6]; [@B83]\
                      - Obtained from turmeric\                                                                                - Decreases intracelullar   ROS levels\                                                 - Decrease in ALS progression   and reduction of oxidative   damage\                                       
                      - Chemical instability\                                                                                  - Eliminates excitability   induced by TDP-43\                                                                                                                                                     
                      - Low oral bioavailability\                                                                              - DMC decreases   mitochondrial dysfunction                                                                                                                                                        
                      - Low water solubility rate\                                                                                                                                                                                                                                                                                
                      - Different types: DMC                                                                                                                                                                                                                                                                                      

  Co-enzyme Q10       \- Endogenous antioxidant                                                                                \- Cofactor of the ETC\                                                                 \- Increases survival rate                                                                                 \
                                                                                                                               - Action in redox balance\                                                                                                                                                                         [@B302]; [@B35]\
                                                                                                                               - Improves mitochondrial   dysfunction                                                                                                                                                             

  Melatonin           \- Amphiphilic molecule\                                                                                 \- Antioxidant\                                                                         \- Delays the progression of the   disease\                                                                [@B529]\
                      - Potent antioxidant                                                                                     - Regulator of mitochondrial   bioenergetic function                                    - Increases the survival rate                                                                              [@B504]

  Edaravone           \- Low-molecular-weight   antioxidant drug\                                                              \- Enhances prostacycling   production\                                                 \- Deletes lipid peroxides and   hydroxyl radicals during   cerebral ischemia\                             [@B209]; [@B30]; [@B519]; [@B321]; [@B2]; [@B28]
                      - Intravenously   administered\                                                                          - Traps hydroxyl radical and   quenches active oxygen                                   - Protects nerve cells within or   around the ischemic region   from free radical damage\                  
                      - Free radical scavenger\                                                                                                                                                                        - Ameliorates OS and   suppresses degeneration of   spinal motor neurons\                                  
                      - Safe\                                                                                                                                                                                          - Anti-inflammatory and   protective effects on neurons,   microglia, astrocytes and   oligodendrocytes\   
                      - Crosses the blood-brain   barrier easily\                                                                                                                                                      - Delays the progression of   functional motor disturbances                                                
                      - High brain penetration   capacity\                                                                                                                                                                                                                                                                        
                      - Amphiphilic capacity\                                                                                                                                                                                                                                                                                     
                      - Scavenges lipid and   water soluble peroxyl   radicals and chain-  carrying lipid peroxyl   radicals                                                                                                                                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Vitamin E {#S5.SS1}
---------

Vitamin E (α-tocopherol) is one of the most studied lipophilic antioxidants due to its ability to cross the cell membrane and the protection that it provides against lipoperoxidation ([@B64]; [@B117]), ROS and RNS ([@B32]) ([Table 1](#T1){ref-type="table"}). The studies on nutritional supplementation with this vitamin have obtained contradictory results.

This antioxidant has been associated with a delay in the clinical onset of the disease ([Table 1](#T1){ref-type="table"}) in transgenic mice that express mutant copies of the gene encoding SOD1 (an animal model of ALS) ([@B184]). Measurements of the erythrocyte activity of the three main radical scavenging enzymes (SOD1, CAT, and GPx) indicated that vitamin E supplementation (300--3000 U/day) in 14 ALS patients did not affect the activity of the three enzymes ([@B378]). One study showed an accumulation of vitamin E in the spinal cord and increased MDA levels over the lifetime of the mouse compared to non-transgenic mice ([@B189]).

In a double-blind placebo-controlled randomized clinical trial, vitamin E did not appear to affect survival and motor function in ALS. However, after 3 months of treatment with vitamin E and riluzole, an increase in plasma GSH levels ([Table 1](#T1){ref-type="table"}) and a decrease in plasma thiobarbituric acid reactive species (TBARS) levels were observed, markers typically altered in the plasma of the patients with ALS ([@B116]). Vitamin E was associated with a slower progression of ALS ([@B350]) and in one study it was observed that regular use of vitamin E supplements was associated with a lower risk of dying by ALS ([@B24]) ([Table 1](#T1){ref-type="table"}).

Other similar studies did not detect significant differences between placebo and the group treated with α-tocopherol and indicated that there are insufficient results to claim that megadoses with vitamin E are effective in slowing the progression of the disease ([@B173]). Supplementation with 600 mg/day of vitamin E did not show differences with respect to the placebo group ([@B157]). In a case-control study with 132 patients suffering from ALS, a significant decrease in the risk of the disease ([Table 1](#T1){ref-type="table"}) was observed when the intake of vitamin E was higher than the average ([@B489]). Supplementation with vitamin E over a prolonged period was associated with lower ALS rates ([@B495]) and a study that included 50 cases of male ALS patients concluded that in men with baseline serum α-tocopherol below the average, there was a non-significant decrease in ALS risk in those receiving α-tocopherol supplementation (50 mg/day) compared to those not receiving α-tocopherol. If baseline serum α-tocopherol was above the average, α-tocopherol supplementation had no effect on the risk of ALS. In this case, α-tocopherol supplementation did not have a significant protective effect on ALS risk ([@B310]).

Carotenes {#S5.SS2}
---------

Carotenes are natural pigments, responsible for the orange, red ([@B255]), yellow or green color of fruits and vegetables ([@B180]) with antioxidant and neutralizing properties against ROS ([@B146]; [@B340]) ([Table 1](#T1){ref-type="table"}).

There is a beneficial association between ALS and the intake of carotenes ([@B348]; [@B336]). Thus, their consumption could help the prevention and/or delay the onset of ALS ([@B148]) ([Table 1](#T1){ref-type="table"}) but in a case-controlled study with 77 Koreans diagnosed with ALS, it was determined that dietary intake of carotenes was negatively associated with ALS ([@B228]). A study conducted in 5 cohorts determined that a higher intake of these pigments was associated with a reduced risk of ALS and that high dietary intakes of ß-carotene and lutein were inversely associated with the risk of suffering from this disease. Astaxanthin and lycopene have shown a beneficial effect in ALS ([@B287]; [@B215]) but in a study with the SOD1^G93A^ mice model of ALS, a tomato-enriched food (rich in lycopene) did not affect disease onset and survival ([@B137]). β-carotene could serve as a potential therapeutic molecule for treating neuroinflammation and apoptosis in ALS patients ([@B256]) ([Table 1](#T1){ref-type="table"}).

Flavonoids {#S5.SS3}
----------

Flavonoids are natural substances mainly present in fruits and vegetables ([@B194]) that have a protective effect against ROS ([@B68]), modulate the activity of different metabolic pathways ([@B296]) ([Table 1](#T1){ref-type="table"}) related to the reduction of cognitive damage and neuronal dysfunction ([@B488]) and suppress neuroinflammation ([@B443]).

7,8-dihydroxyflavone (7,8-DHF) has neuroprotective and regulatory properties on neuromuscular transmission ([@B297]). Chronic administration of 7,8-DHF significantly improved motor deficits and enhanced lower neuronal survival in the transgenic ALS mouse model ([@B252]) ([Table 1](#T1){ref-type="table"}).

Treatment with fisetin reduced intracellular ROS levels, motor neuron loss and improved motor activity and survival rate in three different hSOD1-related mutant models of ALS (Drosophila expressing hSOD1^*G*85R^, hSOD1^G93A^NSC34 cells and transgenic mice hSOD1^G93A^) ([@B499]) ([Table 1](#T1){ref-type="table"}).

Quercetin is an abundant flavonoid in the diet (onion, apple, broccoli and berries) ([@B138]) that has been shown to reduce mitochondrial damage in various animal models of OS. Treatment with quercetin could be a therapeutic strategy for attenuating neuronal death against aluminum-induced neurodegeneration in the rat hippocampus ([@B431]). Quercetin and its derivative, quercetin 3-β-[D]{.smallcaps}-glucoside (Q3BDG), could be therapeutic inhibitors of the aggregation and misfolding of SOD1 associated with ALS ([@B213]) ([Table 1](#T1){ref-type="table"}).

Resveratrol {#S5.SS4}
-----------

Resveratrol (RES) can interact with mutant SOD1 (G93A) protein (a distinctive feature of ALS) ([@B234]; [@B447]; [@B265]) and has positive effects by up-regulating sirtuin 1 (SIRT1) expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of ALS ([@B497]) ([Table 1](#T1){ref-type="table"}). It delays the onset of ALS, increases the survival of spinal motor neurons, preserves the function of the lower and upper motor neuron ([@B292], [@B293]), attenuates the loss of motor neurons and improves muscle atrophy and mitochondrial function of muscle fibers in a SOD1^G93A^ mouse model of ALS ([@B445]) ([Table 1](#T1){ref-type="table"}). One study showed that bone marrow mesenchymal stem cells from ALS patients showed down-regulation of AMPK/SIRT1 signaling, which was recovered by treatment with RES ([@B522]) ([Table 1](#T1){ref-type="table"}).

Epigallocatechin Gallate {#S5.SS5}
------------------------

Epigallocatechin gallate (EGCG) is a catechin present in green tea ([@B87]) and to which an antineurodegenerative and antioxidant effect is attributed ([@B333]; [@B354]), especially on the motor neurons ([@B251]) because it crosses the blood-brain barrier and modulates mitochondrial responses to OS ([@B37]) ([Table 1](#T1){ref-type="table"}). It also protects against lipoperoxidation ([Table 1](#T1){ref-type="table"}) in *in vitro* studies by exposing ROS to the phospholipids of the cell membrane bilayer ([@B464]). It prevents OS-induced death of mutant SOD1 motor neuron cells by alteration of cell survival and death signals ([@B250]). Treatment with EGCG could delay the outbreak or progression of ALS through changes in intracellular signals, increases survival signals (like PI3-K and Akt) and reduces death signals (like GKS-3ß, cytosolic cytochrome c, activated caspase-3 and cleaved poly ADP-ribose polymerase) ([@B268]; [@B294], [@B295]; [@B251]) ([Table 1](#T1){ref-type="table"}). Oral administration of 10 mg/kg of EGCG from a presymptomatic stage delays the onset of the disease and prolongs useful life, in addition to increasing the number of motor neurons, decreasing the activation of the microglia, reducing the concentration of NF-kB, caspase-3 and iNOS in a transgenic mouse model of ALS ([@B510]) ([Table 1](#T1){ref-type="table"}).

Curcumin {#S5.SS6}
--------

Curcumin is a natural and liposoluble dye obtained from turmeric ([Table 1](#T1){ref-type="table"}). It has neuroprotective effects and provides protection against OS ([@B246]), mitochondrial dysfunction, inflammation and protein aggregation ([@B474]; [@B384]; [@B162]).

Curcumin activates nuclear factor erythroid 2-related factor (Nrf2) target genes in primary spinal cord astrocytes, decreases the level of intracellular ROS and attenuates oxidative damage and mitochondrial dysfunction ([@B225]) ([Table 1](#T1){ref-type="table"}). It eliminates the excitability induced by TDP-43 (the major pathological protein in sporadic ALS) in a motor neuron-like cellular model of ALS ([@B290]; [@B126]). Dimethoxy curcumin (DMC) could decrease mitochondrial dysfunction in mutated TDP-43 stably transfected cell lines ([@B289]) ([Table 1](#T1){ref-type="table"}). It binds to the pre-fibrillar aggregates of SOD1, altering its amyloidogenic pathway and decreasing cytotoxicity ([@B44]). Curcumin may improve survival in patients with ALS, especially those with bulbar involvement ([@B6]). In a double-blind therapeutic trial, treatment with curcumin showed a decrease in ALS progression and a reduction of oxidative damage ([@B83]) ([Table 1](#T1){ref-type="table"}).

A study indicates that a drug delivery system based on curcumin will be proposed for the treatment of ALS ([@B471]) but others indicate that the use of curcumin as therapy in ALS has disadvantages: chemical instability and low oral bioavailability and water solubility rate ([@B384]) ([Table 1](#T1){ref-type="table"}). Therefore, it is necessary to develop new technologies to overcome these limitations ([@B282]).

Co-enzyme Q10 {#S5.SS7}
-------------

Co-enzyme Q10 (CoQ10) is an endogenous antioxidant and a cofactor in the ETC ([@B363]) involved in redox balance ([@B513]) ([Table 1](#T1){ref-type="table"}). In the SOD1 transgenic mouse model of ALS, supplementation with CoQ10 extended survival by 6 days and increased brain mitochondrial concentration compared to controls ([@B302]; [@B451]; [@B35]) ([Table 1](#T1){ref-type="table"}). After comparing the plasma redox status of CoQ10 in 20 sALS patients with those in healthy age/sex-matched controls, a significant increase in the oxidized form of CoQ10 in sALS was observed ([@B442]). A study conducted on 31 subjects, showed that treatment with megadoses of 3000 mg/day of CoQ10 over 8 months could improve mitochondrial dysfunction in ALS ([@B143]). However, one study suggested that serum CoQ10 concentrations are unrelated to the risk of ALS ([@B322]; [@B239]).

Melatonin {#S5.SS8}
---------

Melatonin is an amphiphilic molecule that has been identified as a potent antioxidant therapeutic agent in neurodegenerative diseases ([@B370]) associated with mitochondrial dysfunction ([@B161]) ([Table 1](#T1){ref-type="table"}). A study indicated that melatonin could be a candidate for neuroprotection in ALS ([@B219]). In the SOD1^G93A^ transgenic mouse model of ALS, high doses of melatonin administered orally delayed the progression of the disease and increased the survival rate ([@B504]; [@B529]) ([Table 1](#T1){ref-type="table"}). However, evidence suggests that intraperitoneal melatonin is not neuroprotective and may exacerbate neurodegeneration ([@B110]). Clinical trials employing melatonin in the range of 50--100 mg/day are required before its relative merits as a neuroprotective agent are definitively established ([@B353]). Recent studies suggest that riluzole but not melatonin ameliorates acute motor neuron degeneration and moderately inhibits SOD1-mediated excitotoxicity induced disrupted mitochondrial calcium signaling in ALS ([@B220]).

Edaravone {#S5.SS9}
---------

Edaravone is a low-molecular-weight antioxidant drug (Radicava^®^), administered intravenously ([@B363]) which acts as a free radical scavenger ([@B218]) ([Table 1](#T1){ref-type="table"}). In 2015, edaravone was approved for ALS treatment in Japan ([@B347]) and by the Food and Drug Administration of United States in 2017 ([@B501]).

Edaravone easily crosses the blood-brain-barrier and displays a high brain penetration capacity ([@B227]). Its amphiphilic capacity allows edaravone to scavenge both lipid and water soluble peroxyl radicals and chain-carrying lipid peroxyl radicals ([@B329]) ([Table 1](#T1){ref-type="table"}).

The antioxidant mechanisms of edaravone are: enhancement of prostacyclin production, hydroxyl radical trapping and quenching of active oxygen ([@B420]) ([Table 1](#T1){ref-type="table"}). Edaravone eliminates lipid peroxides and hydroxyl radicals during cerebral ischemia, protects nerve cells within or around the ischemic region from free radical damage ([@B2]), ameliorate OS and suppress degeneration of spinal motor neurons ([@B209]). It is attributed anti-inflammatory ([@B28]) and protective effects in neurons, microglia, astrocytes and oligodendrocytes ([@B30]; [@B321]) ([Table 1](#T1){ref-type="table"}).

Investigation of the safety and efficacy of edaravone in 20 ALS patients who received this antioxidant intravenously indicated that this drug is safe and may delay the progression of functional motor disturbances by reducing OS ([@B519]) ([Table 1](#T1){ref-type="table"}).

Nicotinamide Riboside and Neurodegenerative Diseases {#S6}
====================================================

NAD^+^ Role and Levels {#S6.SS1}
----------------------

NAD^+^ is a coenzyme that takes part in critical redox reactions (its reduced form is NADH) for the operation of mitochondrial metabolism ([@B41]; [@B520]). Is an important biological mediator due to its many essential functions for survival: redox reactions, signaling pathways, energy metabolism, mitochondrial function, calcium homeostasis, DNA repair, gene expression ([@B177]; [@B512]), brain metabolism, neurotransmission, learning, memory, axonal neuroprotection ([@B22]; [@B94]; [@B167]) and participation in the NAD^+^/PARP/SIRT1 axis related to aging ([@B307]) ([Figure 2](#F2){ref-type="fig"}).

![Nicotinamide riboside action mechanism. NR gets into the cell and there, it is converted into NAD^+^ through two mechanisms. One of them is Nrk1 and Nrk2 and the other is PNP and NAMPT. NAD^+^ is a cosubstrate of PARPS which is related to repair of DNA damage by ROS. NAD^+^ is also SIRT cosubstrate which is associated with energy metabolism, inflammation regulation, DNA repair and mitochondrial metabolism. The activation of SIRT increases the resistance against OS through an increase in metabolic pathways that detoxify ROS, like SOD2 and Cat. SIRT1 activates PGC-1α which involves an increase of antioxidant defense through SOD2 and GSH. SIRT3 activates SOD2 and Cat. Thus, SIRT regulates mitochondrial function and aging processes as well as is involved in ROS detoxification.](fphys-11-00063-g002){#F2}

NAD^+^ can act as a cosubstrate for sirtuins (SIRT) ([@B491]), class III histone deacetylase enzymes whose activity is dependent on NAD^+^ levels ([@B459]; [@B223]) and for poly(ADP-ribose) polymerases (PARPs), a family of proteins essential for repairing DNA damaged by ROS ([@B432]) ([Figure 2](#F2){ref-type="fig"}).

Sirtuins are related to the metabolic status of cells and are key in cellular metabolism, regulation of the expression of certain genes ([@B346]), energy and mitochondrial metabolism ([@B103]), inflammation and DNA repair ([@B460]). They can be found in the cytoplasm, nucleus and mitochondria ([@B259]). In neurodegenerative diseases and in aging they organize the response to OS and damage to DNA and are related to the functionality of the respiratory machinery and the production of ROS in different tissues ([@B204]).

Activation of SIRT increases resistance to OS ([@B188]) through an increase in metabolic pathways responsible for the detoxification of ROS ([@B414]) such as superoxide dismutase 2 (SOD2), isocitrate dehydrogenase 2 (IDH2) and CAT ([@B463]). They improve metabolic capacity, promote mitochondrial oxidative metabolism and facilitate repair of DNA damage ([@B188]) ([Figure 2](#F2){ref-type="fig"}).

SIRT1 acts on the pathway of the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) ([@B16]; [@B459]), a fundamental regulator of energy metabolism ([@B34]; [@B467]) and mitochondrial dynamics ([@B439]) associated with an increase in antioxidant defenses through SOD2 and GSH ([@B276]; [@B530]; [@B498]) ([Figure 2](#F2){ref-type="fig"}). Reduction of SIRT1 activity compromises oxidative metabolism and antioxidant capacity, affecting complex I of the ETC, mitochondrial function and biogenesis ([@B400]). This effect has been observed in aging and different pathologies: neurodegenerative diseases, metabolic disorders and cancer ([@B387]; [@B199]; [@B223]). In ALS, alterations in SIRT1 levels have been determined in postmortem tissues from patients ([@B253]) and in mouse models of ALS ([@B191]).

Sirtuin 3 (SIRT3) regulates mitochondrial function and the aging processes ([@B61]) by activating SOD2 and CAT ([@B414]) that are involved in the detoxification of ROS ([@B379]; [@B243]) ([Figure 2](#F2){ref-type="fig"}).

The decrease in NAD^+^ levels may be secondary to a defect in its biosynthesis or to depletion ([@B210]) and leads to a deficiency in the activities of SIRTs in the nucleus and mitochondria ([@B75]; [@B165]; [@B306]; [@B153]), reduces the mitochondrial unfolded protein response ([@B307]), disrupts ATP biosynthesis, decreases the ability to pump calcium against the intracellular gradient ([@B65]), disrupts calcium homeostasis, increases excitotoxicity ([@B411]) and has deleterious effects on muscle health ([@B169]).

The lower bioavailability of NAD^+^ levels is involved in many diseases such as neurodegenerative pathologies ([@B139]; [@B229]) and affects the production of energy, lowers the levels of ATP and limits the protection of SIRT1 ([@B201]; [@B66]; [@B210]), an aspect that could worsen in these diseases because of its progressive nature ([@B67]). NAD^+^ levels have been shown to decrease with age, leading to low levels in the brain ([@B532]). Several studies have demonstrated that NAD^+^ metabolism is involved in neuronal function and in the pathophysiology of neurodegenerative diseases ([@B195]) and that NAD^+^ levels in tissues can produce beneficial therapeutical effects in this type of diseases ([@B17]; [@B257]).

The activation of metabolic pathways related to mitochondria and the production of energy through the NAD^+^ and SIRT1 is currently suggested as a therapeutic strategy ([@B517]; [@B460]; [@B383]; [@B528]).

Recovery and/or increase of NAD^+^ levels can protect skeletal muscle from progressive deterioration ([@B150]), reverse the damage to cerebral energy metabolism, increase the protection against OS ([@B288]; [@B58]; [@B491]), promote the activity of SIRTs and proteins involved in mitochondrial function ([@B52]), confers resistance against peroxide toxicity, decreases mitochondrial ROS ([@B192]), protection against neurodegeneration ([@B418]) and upkeep of dependent enzymes that are involved in synaptic plasticity and neuronal stress resistance ([@B266]).

Therefore, the repletion of NAD^+^ levels using precursors can ameliorate this age-associated functional defects ([@B210]), helping to reverse the pathogenic processes characteristic of neurodegenerative diseases ([@B526]).

Precursors of NAD^+^ {#S6.SS2}
--------------------

The precursors of NAD^+^ include nicotinamide mononucleotide (NMN), nicotinamide (NAM), nicotinic acid (NA) and nicotinamide riboside (NR) ([@B192]). Most of the NAD^+^ precursors are more stable and have higher ability to enter neurons than NAD^+^ ([@B418]). NMN and NR are the most used and both have shown an increase in NAD^+^ levels in the cell ([@B338]) ([Table 2](#T2){ref-type="table"}). Most evidence concludes that NR has a greater ability to stimulate a significant increase in NAD^+^ levels ([@B66]) and advantages over the use of other precursors ([Table 2](#T2){ref-type="table"}).

###### 

Comparison between the different NAD^+^ precursors.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NAD^+^ precursor                    Advantages                                                                                               Disadvantages                                              References
  ----------------------------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------
  Niacin (NA)                         \- Prevents Pellagra\                                                                                    \- Produces cutaneous   flushing\                          \
                                      - Regulation of lipid levels (total   cholesterol, triglycerides and LDL)                                - Not a NAD^+^ precursor in   the majority of the cells\   [@B111]; [@B181]; [@B377]

  Nicotinamide mononucleotide (NMN)   \- One of the most used\                                                                                 \- No consensus on how is   transported to the cell\       [@B338]; [@B176]; [@B423]
                                      - Has shown an increase in NAD^+^   levels in the cell                                                                                                              

  Nicotinamide (NAM)                    Can be a stimulator in cells                                                                             Smaller increase in NAD^+^   compared to NR              [@B66]

  Nicotinamide riboside (NR)          \- Action on\                                                                                              No evidence                                              \
                                        mammalian cells\                                                                                                                                                  [@B514]; [@B50]; [@B66]; [@B468]; [@B8]; [@B299]\
                                      - Minimal toxicity\                                                                                                                                                 
                                      - High bioavailability\                                                                                                                                             
                                      - High capacity to cross the blood-  brain barrier\                                                                                                                 
                                      - Supports neuronal NAD^+^ synthesis\                                                                                                                               
                                      - Greater ability to stimulate a   significant increase in NAD^+^ levels   and intermediate precursors                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA prevents Pellagra ([@B377]) and has positive effects on the regulation of lipids (total cholesterol, triglycerides and LDL) ([@B181]) (Tabla 2). However, produces cutaneous flushing and does not work as NAD^+^ precursor in the majority of cells ([@B111]) ([Table 2](#T2){ref-type="table"}). One of the most important advantages of NR over NA is that supports neuronal NAD^+^ synthesis ([@B50]) and has action on several types of cultured mammalian cells, including mouse and human cells ([@B514]) ([Table 2](#T2){ref-type="table"}).

There is no consensus on how NMN is transported to the cell ([@B176]; [@B423]) ([Table 2](#T2){ref-type="table"}). However, NR is five times more effective than NMN in increasing intracellular NAD^+^ levels in skeletal muscles ([@B344]) ([Table 2](#T2){ref-type="table"}).

After comparing NR with NA and NAM in mice, NR showed a significant higher peak of NAD^+^ concentration and a significant increase of intermediate NAD^+^ precursors including NMN, NA mononucleotide and NA adenine dinucleotide ([@B468]) ([Table 2](#T2){ref-type="table"}). NR has a different time course compared to NAM and NA and produces more NAD^+^ than the other precursors in equivalent doses ([@B468]). NR increases the ratio of NAD^+^/NADH more significantly compared NMN, NAM and NA and this can contribute to improving the oxidative capacity of mitochondria ([@B66]) and to decrease the rate of oxidative damage against DNA and mitochondrial stress ([@B385]; [@B448]; [@B125]) ([Table 2](#T2){ref-type="table"}).

NR is a nucleoside that incorporates a nicotinamide and a ribose ([@B38]; [@B82]) group. It is a trace nutrient known as vitamin B3 ([@B264]), available in certain foods (dairy products, fish, eggs, and vegetables) ([@B318]), nutritional supplements and fortified foods ([@B92]). Its effects are associated with energy metabolism and neuroprotection ([@B82]). When the NR enters the cells it is converted to NAD^+^ by at least two types of metabolic pathway. The first requires the participation of the nicotinamide riboside kinases (NRKs) ([@B82]) in two of its isoforms (NRK1 and NRK2) ([@B47]) and the second requires the action of purine nucleoside phosphorylase (PNP) and nicotinamide phosphoribosyltransferase (NAMPT) ([@B63]) ([Figure 2](#F2){ref-type="fig"}).

The conversion of NR into NAD^+^ has been observed in animal tissues of muscle and brain ([@B82]) and treatment by exogenous supplementation of NR is able to increase intracellular concentrations of NAD^+^ and promote its beneficial effects ([@B55]) ([Figure 2](#F2){ref-type="fig"}). NR enhances protection against aging and related diseases, with positive results on longevity in multiple animal models ([@B326]; [@B371]) and has been recently reported that NR protects against excitotoxicity induced axonal degeneration ([@B487]). The increase of NAD^+^ levels by supplementation with precursors such as NR improves mitochondrial and muscular function and the function of neuronal cells in mice ([@B307]). A study performed in mice supplemented nutritionally with 400 mg/kg/day of synthetic NR showed an increase in NAD^+^ levels in muscle and liver tissue ([@B66]). As NR increases the NAD^+^/NADH ratio, it could be related to an improvement of the oxidative capacity of the mitochondrial pathway and could be a therapeutic strategy of interest in those diseases that are associated with mitochondrial dysfunction and OS such as neurodegenerative diseases ([@B66]). Improvement of NAD^+^ levels provides greater mitochondrial resistance against OS ([@B515]) and prevents cell death due to the protective function of SIRT3 ([@B187]), which stimulates SOD, responsible for enhancing the "detoxification" of ROS ([@B80]) ([Figure 2](#F2){ref-type="fig"}).

Supplementation with NR is safe in mice and humans and has minimal toxicity, high bioavailability and high capacity to cross the blood-brain barrier ([@B468]; [@B8]; [@B299]) ([Table 2](#T2){ref-type="table"}).

Nicotinamide Riboside {#S6.SS3}
---------------------

Neurodegenerative diseases are associated with a progressive decrease in muscle mass and strength and an increase in their weakness ([@B168]; [@B480]; [@B108]). Muscle contractility dysfunction precedes the loss of motor unit connectivity in the SOD1^G93A^ mouse model of ALS ([@B505]) with neurodegeneration being one of the determinant risk factors for muscle quality ([@B118]; [@B323]). Treatment with NR improves muscle function in aged mice ([@B66]) and has benefits on muscle strength and skeletal muscle resistance in knock out mice that have specific elimination of NAMPT and a decrease of 85% in the intramuscular content of NAD^+^ ([@B153]). This would indicate that the maintenance of NAD^+^ homeostasis is critical for muscle mass and its contractile function ([@B306]; [@B153]). NR induces rejuvenation in muscle and brain stem cells ([@B410]) and an increase in neurogenesis and muscle function ([@B526]). NAD^+^ is a fundamental modulator of muscle senescence and after treatment with NR, there is an acceleration of muscle regeneration in both young and old mice and an improvement in running times, maximum distances, grip strength of the extremities of aged mice and increased expression of cell cycle genes ([@B526]).

Levels of PGC-1α are decreased in Alzheimer's disease (AD) and this is related to the formation of ß-amyloid plaques and greater deposition of this substance (main characteristics of AD) ([@B507]; [@B380]). Studies conducted in animal models of AD established a relationship between the levels of NAD^+^ and a decrease in the toxicity of the amyloid substance ([@B245]; [@B380]). For this reason, the therapeutic strategy based on nutritional supplementation with NR could be of interest in AD cases to stop the onset and progression of the dementia ([@B400]) and to improve cognitive function and synaptic plasticity by promoting the function of PGC-1α as demonstrated in Tg2576 mice (mouse model of ALS) ([@B167]). After analyzing the effect of NR on the physiopathology and cellular mechanisms in the 3xTgAD/Polß^±^ mouse model (mice deficient in DNA repair that exacerbates the main characteristics of AD in humans) it was observed that supplementation with NR significantly increased the NAD^+^/NADH ratio, reduced neuroinflammation, apoptosis and damage to DNA, increased neurogenesis, restored synaptic plasticity, improved learning capacity and reversed memory deficits ([@B198]). Treatment with NR improves cognition in transgenic mice with AD by reducing the phosphorylation of the Tau protein (pTau) (a form that accumulates in the brain of AD patients and is the hallmark of the disease) ([@B174]; [@B407]; [@B341]). In the case of PD, the repletion of NAD^+^ through the use of NR prevents aging related to the loss of dopaminergic neurons and the reduction of motor function in Drosophila fly model of PD ([@B435]). NR improves mitochondrial function in PD neurons, increases the markers of mitochondrial biogenesis, significantly decreases the production of mtROS (mitochondrial ROS), reduces mitochondrial membrane potential and increases the levels of NAD^+^ and NADH ([@B425]).

Axonal degeneration occurs in most neurodegenerative diseases (AD, PD, ALS) ([@B382]; [@B93]). The increase in NAD^+^ synthesis through the use of precursors such as NR promotes axonal protection ([@B496]; [@B418]). Improvement of the NAD^+^ recovery pathway reverses the toxicity of primary astrocytes expressing the SOD1 mutation related to ALS, decreasing the mitochondrial production of ROS and reversing the neurotoxic effects ([@B192]). Excitotoxicity is a process that takes place in most neurodegenerative disorders like ALS and is related to strong NAD^+^ depletion in neurons. NR protects against excitotoxicity-induced axonal generation ([@B487]).

In Duchenne's muscular dystrophy disease, supplementation with NR reverses progressive wear and improves resistance in skeletal muscle NAMPT in the knock out mouse model ([@B410]).

Pterostilbene and Neurodegenerative Diseases {#S7}
============================================

Polyphenols are organic metabolites present in plants ([@B101]) and widely distributed in a variety of dietary sources ([@B5]; [@B248]): fruits, vegetables, legumes, whole grains, seeds, nuts, extra virgin olive oil, red wine, coffee, tea, chocolate, herbs and spices ([@B409]; [@B156]; [@B390]; [@B479], [@B478]; [@B456]). Despite their zero energy contribution ([@B408]) they act as bioactive dietary components associated with multiple positive health effects ([@B21]; [@B160]; [@B454]; [@B393]) due to their regulating action on metabolism, chronic diseases and cell proliferation ([@B470]). Polyphenols have a chemical structure with properties that make them the compounds with the greatest antioxidant action: *o*-diphenolic group, 2-3 double bond conjugated with the 4-oxo function and hydroxyl groups (OH) in positions 3 and 5 ([@B408]). They have antioxidant ([@B203]; [@B461]), anti-inflammatory ([@B349]), anticarcinogenic ([@B335]), antiallergic ([@B236]), antibiotic ([@B509]), and immunomodulatory ([@B342]) properties.

Polyphenols can be a useful therapeutic strategy in pathologies that present OS such as neurodegenerative diseases ([@B46]; [@B386]; [@B391]; [@B72]), cancer and cardiovascular diseases ([@B106]; [@B62]; [@B262]). Taking into account that nutrition is a factor that modulates processes such as cognition or progression of CNS diseases ([@B185]; [@B205]), polyphenols have recently been associated with: prevention, repair of oxidative damage ([@B263]), synaptic plasticity, neuronal signaling and autophagy ([@B315]; [@B375]).

Among the polyphenols with important pharmaceutical activity are the stilbenes ([@B132]), a group of non-flavonoid phytochemicals of polyphenolic structure with a 1,2-diphenylethylene core, which are produced naturally in plants via the phenylpropanoid pathway ([@B440]) to protect the plant from fungal infection and toxins ([@B9]). There is a wide variety of forms because of a common structure to which various substituents can be added in different positions and they have an acidic and amphiphilic character ([@B332]). Although the *trans* isomer is the most common form of presentation (since it is the most stable), it can also be found in the *cis* isomer ([@B398]). The following properties have been attributed to them: antioxidant, anti-inflammatory, neuroprotective, cardioprotective, anti-carcinogenic ([@B263]), hypolipidemic and anti-diabetic ([@B493]; [@B453]). They have great utility potential in the field of neurodegenerative diseases. They reduce the formation of amyloid plaques in the brain, decrease the production of ROS and could be of interest in other situations such as: ischemia-reperfusion injury, atherosclerosis, diabetes, cancer, obesity, platelet aggregation, blood pressure, depigmentation and cardiomyocyte and cardiac hypertrophy ([@B465]; [@B166]; [@B533]; [@B183]; [@B9]).

One of the most studied stilbenes has been Resveratrol (RES) (3,5,4'-trihydroxy-trans-stilbene), due to its benefits in cardiovascular health ([@B533]; [@B53]; [@B133]). However, recent studies focus their interest on pterostilbene (PTER) (trans-3,5-dimethoxy-4hydroxystilbene), a dimethylated natural stilbene ([@B11]) with 1 hydroxyl group and 2 methoxy groups ([@B88]; [@B140]; [@B469]), which provides greater oral bioavailability, half-life, lipophilicity and higher permeability to targeted tissue ([@B237]; [@B518]) with respect to RES (3 hydroxyl groups). In addition, PTER is less susceptible to phase II liver metabolism ([@B531]). These particular characteristics improve its biological potential ([@B518]) and its high bioavailability *in vivo* is an advantage over RES ([@B85]; [@B69]; [@B279]). PTER presents a bioavailability of 80% compared to 20% for RES and plasma levels of PTER and PTER sulfate were significantly higher than plasma levels of RES and RES sulfate in a mouse model ([@B237]). After administration of PTER and RES at the same dose to male and female mice for 8 weeks, PTER reached higher concentrations in the serum and in the brain than RES ([@B76]).

The high lipophilicity of PTER allows it to easily cross the blood-brain barrier ([@B462]), resulting in greater neuroprotection than RES ([@B86]). In AD, PTER presents superior neuroprotection than RES ([@B76]) and is the stilbene with the highest inhibitory potential for 5-lipoxygenase (5-LOX) ([@B261]), decreasing the levels of lipid and protein oxidation ([@B107]). It is a more potent anticancer and anti-inflammatory agent than RES ([@B85]) and it distributes widely among the main target organs (brain, liver, kidney, heart and lung) for what seems to be a promising ([@B86]) and safe ([@B396]) therapeutic strategy. A study in male and female Swiss mice examined the sub-chronic toxicity and the possible adverse effects of PTER and concluded that, even with the highest dose administered, PTER was not toxic ([@B408]).

Molecular Mechanisms of PTER {#S7.SS1}
----------------------------

The physiological activities of PTER include: antioxidant and anti-inflammatory activity, ability to restore intracellular calcium and cognitive function ([@B275]) ([Figure 3](#F3){ref-type="fig"}).

![Pterostilbene properties and action mechanism. The antioxidant mechanism of Pter is associated with Cat, GSH, SOD, Nrf2 and SIRT1 pathways, which leads to an inhibition of the oxidation and lipoperoxidation processes, decreasing the levels of MDA, HNE, 8-OHdG and carbonilated proteins. Its action on NF-kß involves an anti-inflammatory effect due to the decrease in the levels of TNF-α and interleukins such as IL-1β, IL-6 and IL-18. Its role on NF-kß, LPS and PPAR-α mediates the cognitive function of Pter, which is expressed through cognition modulation, inhibition of microglia activation and protection against neuronal damage. In addition, Pter presents protection against excitotoxicity due to the increase in cellular restoration and the reduction of the recovery time after cellular depolarization.](fphys-11-00063-g003){#F3}

### Antioxidant Activity {#S7.SS1.SSS1}

PTER stands out for its antioxidant action against numerous types of free radicals: HO, H~2~O~2~ ([@B73]; [@B311]; [@B3]) and NO^∙^ ([@B352]; [@B527]). It is able to neutralize metal-induced radicals ([@B405]; [@B419]) and to inhibit oxidation and lipoperoxidation processes ([@B397]) causing a decrease in carbonylated proteins and oxidation by-products: MDA, HNE and 8-OHdG ([@B275]) ([Figure 3](#F3){ref-type="fig"}). The administration of PTER improves the antioxidant defenses of the brain by raising the levels of CAT, GSH and the activity of SOD ([@B330]) ([Figure 3](#F3){ref-type="fig"}). In addition, diet supplemented with PTER increases the expression of SOD2 ([@B120]). Pre-treatment with PTER has a potent antioxidant function that increases SOD activity in hypoxic-ischemic brain injury in the P7 rat model ([@B269]). Treatment with PTER reduces glutamate-induced OS injury by reducing ROS and increasing the function of SOD and GSH by activating the Nrf2 signaling pathway in neuronal cells ([@B494]), a target factor for the prevention of diseases related to aging such as neurodegenerative diseases ([@B42]; [@B275]) ([Figure 3](#F3){ref-type="fig"}).

The potent antioxidant mechanism of PTER is associated with SIRT1 signaling activation ([@B271]; [@B183]; [@B283]) leading to the attenuation of the skeletal muscle OS injury and mitochondrial dysfunction induced by ischemia-reperfusion injury in male Sprague-Dawley rats ([@B81]). PTER acts on Nrf2 ([@B419]; [@B525]; [@B511]) and attenuates high glucose-induced central nervous system injury *in vitro* through the activation of Nrf2 signaling, displaying protective effects against mitochondrial dysfunction-derived OS ([@B516]).

### Anti-inflammatory Activity {#S7.SS1.SSS2}

PTER has been recognized as an anti-inflammatory agent ([@B392]; [@B376]; [@B254]) able to protect neurons against neuroinflammation due to the inhibition of ROS production ([@B434]). It acts on NF-kB and suppresses the action of various proinflammatory cytokines: TNF-α, IL-1β, IL-6 and IL-18 ([@B88]; [@B358]; [@B200]; [@B135]) ([Figure 3](#F3){ref-type="fig"}). PTER inhibits amyloid-β-induced neuroinflammation in microglia by inactivating the NLRP3/caspase-1 inflammasome pathway and reduces the secretion levels of IL-6, IL-1β and TNF-α, thereby attenuating the neuroinflammatory response, which would indicate that it could be a useful therapeutic strategy in neurodegenerative diseases ([@B272]; [@B428]).

### Ability to Restore Intracellular Calcium {#S7.SS1.SSS3}

PTER is able to increase the capacity of intracellular calcium restoration by reducing recovery time after cell depolarization ([@B231]). It protects against excitotoxicity, an aspect that would be interesting since it has been observed that the increase in intracellular ROS levels is related to damage in the cell membrane, impaired calcium homeostasis ([@B466]; [@B232]) and increased excitotoxicity ([@B411]) ([Figure 3](#F3){ref-type="fig"}). In the Sprague-Dawley rat model, PTER improves cholinergic transmission due to the decrease in the activity of acetylcholinesterase and increases the action of ATPases (Na^+^, K^+^, Ca^2+^, and Mg^2+^), which is indicative of the maintenance of the cell membrane potential ([@B330]).

### Cognitive Function {#S7.SS1.SSS4}

After determining if PTER was effective in reversing the effects of aging in old Fischer rats, it was concluded that memory functioning was related to PTER levels in the hippocampus and that a diet supplemented with this antioxidant is effective in reversing deficits in cognitive behavior ([@B231]). PTER attenuated lipopolysaccharide (LPS) induced learning and memory impairment, which is associated with an inhibition of the activation of microglia and therefore a protective effect against neuronal damage ([@B200]) ([Figure 3](#F3){ref-type="fig"}). It reduces memory loss in the intracerebroventricular administered streptozotocin-induced memory decline in Sprague--Dawley rats ([@B330]) and mediates neuroprotection against oxidative toxicity via the estrogen receptor signaling pathway in human neuronal SH-SY5Y cells ([@B446]).

In AD, supplementation with PTER reduces the phosphorylation of pTau ([@B374]). The derivatives of PTER showed antioxidant and inhibitory activity against the aggregation of β-amyloid plaques, as well as cholinesterase inhibition, which would be useful in the treatment of patients with AD ([@B274]) and vascular dementia ([@B263]).

PTER is a modulator of cognition and the OS due to the increased expression of peroxisome proliferator activator receptor alpha (PPAR-α) ([@B76]) ([Figure 3](#F3){ref-type="fig"}). After comparing the effectiveness of dietary supplementation with RES and PTER in the improvement of functional deficits characteristic of AD in the SAMP8 mouse model (a model of accelerated aging that is increasingly being validated as a model of sporadic and age-related AD), it was concluded that PTER and not RES, is able to modulate the markers of cellular stress and inflammation, causing an upregulation of PPAR-α ([@B76]) and a suppression of the activation of NF-kB ([@B212]), which is a conservative factor against the loss of cognitive function ([@B222]; [@B200]) ([Figure 3](#F3){ref-type="fig"}).

Due to the activation of metabolic pathways related to OS protection, inflammation, regulation of excitotoxicity and preservation of neuronal functions, PTER is a protective factor against neurodegenerative diseases ([@B376]).

Conclusion {#S8}
==========

OS is involved in neuroinflammation, development and progression of ALS. The complex interaction between all the factors does not allow definitive determination if OS is a primary cause or if it is a secondary effect to the propagation of damage in the nervous cells. However, a clear relationship has been established between OS, mitochondrial dysfunction and neuroinflammation, aspects that promote a "vicious cycle" that causes a decrease in the capacity of ATP biosynthesis and an increase in ROS levels.

Currently, there is no cure for ALS but the use of different antioxidant substances has been proposed as a possible therapeutic strategy, the purpose of which is to increase the body's antioxidant defenses and maintain the redox balance. However, there are cases in which the use of these antioxidants has disadvantages or requires a higher number of studies since few results are available or these are contradictory, inconclusive or scarcely significant at the statistical level. Taking into account the pathogenic mechanisms of ALS, the new therapeutic strategies have as the main goal to activate the metabolic pathways related to the mitochondria, production of energy and increase the antioxidant defense levels.

NAD^+^ acts on energy metabolism, mitochondrial function and is key in brain metabolism, aspects involved in the pathogenesis of ALS. Restoration of NAD^+^ levels by administrating the precursor NR provides greater mitochondrial resistance against impairment of redox balance and, therefore, could play a key role in those diseases that are associated with mitochondrial dysfunction and OS.

PTER has great biological potential due to its ability to activate metabolic pathways related to protection against OS, mitochondrial dysfunction, inflammation, intracellular calcium restoration and cognitive function, thus resulting in a neuroprotective function against the pathogenic mechanisms of ALS.

In a randomized, double-blind, placebo-controlled study in humans, it was determined that repeated doses of a combination therapy with NR and PTER increased NAD^+^ levels safely and effectively ([@B114]). Treatment with NR and PTER is effective and safe and therefore it could be a promising therapeutic strategy in ALS, due to its action on the pathogenesis of this disease.
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